Worth reading
66In focus
Scored from 4 of 5 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Details of issuance or disposal
Amount of funds to be raised
Estimated net proceeds from the domestic offering: ¥1,856 million; estimated net proceeds from the overseas offering: ¥1,082 million; maximum estimated net proceeds from the third-party allotment: ¥504 million; maximum total estimated net proceeds: ¥3,444 million
Specific use of funds
Research and development funding primarily for developing therapeutic applications in the DTx product business and conducting clinical trials for various development pipelinesAmount ¥1,916 million / Scheduled timing of expenditures ¥1,167 million through the fiscal year ending June 2026; ¥435 million in the fiscal year ending June 2027; ¥314 million from the fiscal year ending June 2028 onward
Recruitment expenses and personnel expenses, including fees paid to recruitment agencies, to strengthen the organizational structures of the systems development, clinical development, business development and administrative divisionsAmount ¥1,240 million / Scheduled timing of expenditures ¥816 million through the fiscal year ending June 2026; ¥311 million in the fiscal year ending June 2027; ¥113 million from the fiscal year ending June 2028 onward
Costs related to expanding office space, which will inevitably be required as headcount increasesAmount ¥288 million / Scheduled timing of expenditures ¥154 million through the fiscal year ending June 2026; ¥116 million in the fiscal year ending June 2027; ¥18 million from the fiscal year ending June 2028 onward
Most recent equity financing
Public offering in connection with the initial public offering on 24 December 2021
Impact on Business Performance
The impact on results for the fiscal year ending June 2027 is immaterial
| Item | Details |
|---|---|
| Amount of funds to be raised | Estimated net proceeds from the domestic offering: ¥1,856 million; estimated net proceeds from the overseas offering: ¥1,082 million; maximum estimated net proceeds from the third-party allotment: ¥504 million; maximum total estimated net proceeds: ¥3,444 million |
| Specific use of funds | Details Research and development funding primarily for developing therapeutic applications in the DTx product business and conducting clinical trials for various development pipelines / Amount ¥1,916 million / Scheduled timing of expenditures ¥1,167 million through the fiscal year ending June 2026; ¥435 million in the fiscal year ending June 2027; ¥314 million from the fiscal year ending June 2028 onward, Details Recruitment expenses and personnel expenses, including fees paid to recruitment agencies, to strengthen the organizational structures of the systems development, clinical development, business development and administrative divisions / Amount ¥1,240 million / Scheduled timing of expenditures ¥816 million through the fiscal year ending June 2026; ¥311 million in the fiscal year ending June 2027; ¥113 million from the fiscal year ending June 2028 onward, Details Costs related to expanding office space, which will inevitably be required as headcount increases / Amount ¥288 million / Scheduled timing of expenditures ¥154 million through the fiscal year ending June 2026; ¥116 million in the fiscal year ending June 2027; ¥18 million from the fiscal year ending June 2028 onward |
| Most recent equity financing | Public offering in connection with the initial public offering on 24 December 2021 |
| Impact on Business Performance | The impact on results for the fiscal year ending June 2027 is immaterial |
Items this document does not state (24)
Type of issuance or disposalNumber of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueEstimated issuance expensesPayment dateIntended allotteeIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offering
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To advance the clinical development of multiple development pipelines, continue hiring activities to strengthen the organizational structure, and relocate the office in preparation for medium- to long-term growth in headcount.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.